Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | CTSH | P09668 | 1/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.49 |
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.49 |
| ▸ | CCKAR | P32238 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.48 |
| ▸ | GLP1R | P43220 | 3/20 | 0.47 |
| ▸ | MC4R | P32245 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489380 | 0.96 | CTSL (0.53) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL30264772 | 0.91 | C5AR1 (0.51) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL30104393 | 0.91 | CTSL (0.47) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL30725657 | 0.91 | C5AR1 (0.52) | C5AR1IL23RGLP1RMC4R | |
| SCHEMBL29484310 | 0.90 | CTSL (0.53) | CTSLCTSSCTSKCTSHIL23R | |
| SCHEMBL30388309 | 0.90 | IL23R (0.53) | CTSLCTSSCTSKCTSHIL23R | |
| SCHEMBL29511006 | 0.89 | C5AR1 (0.52) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL29476447 | 0.89 | MC4R (0.50) | C5AR1CCKARCCKBRMC4R | |
| SCHEMBL29476484 | 0.89 | MC4R (0.50) | C5AR1CCKARCCKBRMC4R | |
| SCHEMBL30518049 | 0.89 | C5AR1 (0.53) | CTSLCTSSCTSKCTSHC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712460-B2 | Methods of treating chronic disorders with complement inhibitors | APELLIS PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712460-B2 | Methods of treating chronic disorders with complement inhibitors | C5, C3AR1, C1QBP | CTSL 432/4885CTSS 889/4885CTSK 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.